ADAPTHEALTH CORP AHCO 深 沪
已收盘 05-15 16:00:00 美东时间
10.66
-0.080
-0.74%
华盛通- 最 高10.78
- 今 开10.78
- 成交量 113.07万股
- 最 低 10.56
- 昨 收 10.74
- 总市值 14.50亿
- 52周最高 13.43
- 市盈率 静 --
- 换手率 0.83%
- 52周最低 8.06
- 委 比 41.51%
- 总股本 1.36亿
- 历史最高 41.579
- 量 比 0.68
- 振 幅 2.05%
- 历史最低 6.37
- 每 手 1
- 风险率 1.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
UBS Maintains Buy on AdaptHealth, Lowers Price Target to $14
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $15 to $14.
05-07 05:34
AdaptHealth shares are trading lower after the company reorted mixed Q1 financial results.
AdaptHealth shares are trading lower after the company reorted mixed Q1 financi...
05-05 21:21
AdaptHealth Raises FY2026 Sales Guidance from $3.440B-$3.510B to $3.450B-$3.520B vs $3.463B Est
AdaptHealth (NASDAQ:AHCO) raises FY2026 sales outlook from $3.440 billion-$3.510 billion to $3.450 billion-$3.520 billion vs $3.463 billion estimate.
05-05 19:16
AdaptHealth Q1 Adj. EPS $(0.50) Misses $0.02 Estimate, Sales $819.799M Beat $796.621M Estimate
AdaptHealth (NASDAQ:AHCO) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $0.02 by 2600 percent. This is a 900 percent decrease over losses of $(0.05) per share from the same
05-05 19:16
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
Truist Securities Maintains Buy on AdaptHealth, Raises Price Target to $14
Truist Securities analyst David Macdonald maintains AdaptHealth (NASDAQ:AHCO) with a Buy and raises the price target from $13 to $14.
04-14 00:54
